Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
Verified 2026-10-06 · 3 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [11] Sperling R Salloway S Brooks DJ Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 2012 11 241 9 22305802 PMC4063417 source
The Methods identify the scans as coming from phase 2 bapineuzumab studies 201 and 202 and their extension study 251. The Results report that ARIA-E incidence increased with both bapineuzumab dose and the number of APOE ε4 alleles. Page numbers are not available in our copy. (LLM, conf=0.94)
- Supportedcites [13] Salloway S Sperling R Gilman S A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 2061 70 19923550 PMC2790221 source
The Abstract reports that MRI-detected vasogenic edema was more frequent in higher bapineuzumab dose groups. The Safety section reports increasing edema rates with APOE ε4 gene dose: 4.3% with zero copies, 7.1% with one, and 33.3% with two. The supplied passages do not give page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) identify 3D6 as an antibody that reduced plaque burden in PDAPP transgenic mice. They do not report that 3D6 improved memory; the paper’s mention of improved object-recognition performance concerns a different antibody directed against the midportion of Aβ. (LLM, conf=0.86)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The Results report that 3D6 treatment protected synapses in transgenic PDAPP mice, and Figure 4 (Discussion; page not specified) reports improved synaptophysin levels. The paper does not report a memory test or show that 3D6 improved memory; synaptic protection does not establish that outcome. (LLM, conf=0.84)
- Could not verifycites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The antibody-results passage (section labeled Abstract; page unavailable) reports that 3D6 precipitated soluble Aβ and prevented a synaptic-plasticity deficit. The memory experiment in the same section used normal rats and did not test 3D6. Searches for 3D6 and for antibody treatment in transgenic mice found no passage showing that 3D6 improved their memory. (LLM, conf=0.76)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Results section, “The N-terminal anti-Aβ mAb 3D6 acutely reverses CFC deficit in Tg2576 mice” (Fig. 6), reports that 3D6 completely reversed a contextual fear-conditioning deficit in transgenic mice overexpressing human amyloid precursor protein. The Introduction identifies 3D6 as the murine antibody from which bapineuzumab was humanized. Together, these passages support the attributed improvement in a memory-related task. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [2] Bateman RJ Xiong C Benzinger TL Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012 367 795 804 [Erratum, N Engl J Med 2012;367:780.] 22784036 PMC3474597 source
The Results (Combined Model) report Aβ deposition detected at least 15 years before expected symptom onset in mutation carriers. The Discussion also says amyloid deposition probably occurs years or decades before dementia symptoms in sporadic Alzheimer’s disease. (LLM, conf=0.93)
- Supportedcites [26] Jack CR Jr Knopman DS Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 2010 9 119 28 20083042 PMC2819840 source
In “Biomarker abnormalities precede clinical symptoms,” the paper says that calculated rates from serial PiB imaging indicate Aβ-plaque accumulation might begin as much as two decades before clinical symptoms in individuals destined to develop dementia. That supports the cited claim’s qualified wording, “probably starts many years before.” The separate treatment claim in the citing sentence is attached to citation 28, not this source. (LLM, conf=0.94)
- Not checked yetcites [27] Villemagne VL Burnham S Bourgeat P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 source
The Results and Discussion (page unavailable) identifies 3D6 among antibodies previously effective at reducing plaque burden in vivo. The paper describes those brain plaques as containing Aβ, supporting the attributed preclinical reduction in brain Aβ. (LLM, conf=0.88)
- Supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 source
The Results report significantly reduced brain Aβ levels after passive immunization with N-terminal anti-Aβ antibodies. The Methods identify 3D6 as an anti-Aβ(1–5) antibody, and the Figure 4 caption confirms that PDAPP mice received 3D6 as a passive immunization treatment. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The passage on antibody co-administration (section labeled Abstract; page unavailable) reports that 3D6 almost completely precipitated soluble Aβ from extracts of human Alzheimer’s brains. That is an ex vivo finding, not evidence that administering 3D6 reduces Aβ levels in the brain in preclinical animals. (LLM, conf=0.78)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Abstract reports that preclinical studies of 3D6, the murine form of bapineuzumab, demonstrated resolution of Aβ plaque and vascular burdens in transgenic mice. The Introduction likewise describes enhanced clearance of insoluble Aβ in the brain and cerebral vasculature, supporting the claim that 3D6 reduces brain Aβ. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
Table 1 in Results and Discussion (page unavailable) reports that 3D6 binds amyloid plaques in PDAPP mice, supporting binding to deposited Aβ. It does not report that 3D6 binds oligomeric or monomeric Aβ; the aggregated-versus-soluble binding measurements concern other antibodies. (LLM, conf=0.82)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The antibody-generation section identifies 3D6 as an antibody against Aβ(1–5), and the methods describe its use to stain amyloid plaques. Our copy does not establish that 3D6 binds each of the fibrillar, oligomeric, and monomeric forms of Aβ; searches for those forms found no binding results. (LLM, conf=0.83)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The paper reports that 3D6 immunoprecipitated soluble Aβ from Alzheimer’s brain extracts; its discussion of 3D6-immunoprecipitated material includes dimers and monomers (Abstract, page unavailable). Our copy does not show that 3D6 binds fibrillar Aβ, so the claim’s full list of forms is not supported. (LLM, conf=0.84)
- Partly supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 sourceExperimental — accuracy not yet measured
The section “Binding of the N-terminal antibody 3D6 to soluble Aβ species” reports that 3D6 binds soluble, oligomer-enriched Aβ. The Introduction describes clearance of insoluble Aβ, but the passages do not establish direct binding to fibrillar or monomeric Aβ. Those two specified forms are therefore not fully supported by this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 57 claims and to verify the 18 references still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the completion of the first two studies, which revealed no treatment efficacy on either cognitive or functional outcomes, further trials were halted (Salloway et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bapineuzumab was the first monoclonal antibody to target Aβ in AD using a passive immunotherapy technique.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement [99].”
From Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology (2023) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further trials were discontinued after the first two trials were completed and yielded no treatment effect on either cognitive or functional outcomes [41].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 501–600 of 1,014
Li, S., Jin, M., Liu, L., Dang, Y., Ostaszewski, B. L., & Selkoe, D. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0626-x · Cited by 63
“Unfortunately, several antibodies targeting Aβ have failed in clinical trials, including bapineuzumab [57], a humanized monoclonal antibody directed against the N-terminus of Aβ that recognizes the amyloid beta 1–5 region [41], similar to murine monoclonal antibody 3D6.”
Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study
Franco-Bocanegra, D. K., George, B., Lau, L. C., Holmes, C., Nicoll, J. A. R., & Boche, D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0828-x · Cited by 64
“reported after immunotherapy, known as amyloidrelated imaging abnormalities (ARIA) including microhaemorrhages and oedema [5, 43].”
Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.
Pizzo, M. E., Plowey, E. D., Khoury, N., Kwan, W., Abettan, J., DeVos, S. L., Discenza, C. B., Earr, T., Joy, D., Lye-Barthel, M., et al. (2025) · Science · doi:10.1126/science.ads3204 · Cited by 63
Xu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 70
“However, no significant improvement in cognitive function was observed in mild-to-moderate AD patients treated with bapineuzumab during a large-scale phase 3 clinical trials (Salloway et al., 2014).”
BackgroundAlkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
“Because of the high rate of symptomatic ARIA-E at doses >2 mg/kg, the drug’s development was stopped early [119].”
InfluentialGene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease
Saura, C. A., Parra-Damas, A., & Enriquez-Barreto, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00318 · Cited by 65
“Alternatively, anti-amyloid immunotherapy treatments that efficiently reduce amyloid plaque burden fail to improve cognitive performance in mild-to moderate AD patients (Doody et al., 2014; Salloway et al., 2014).”
BackgroundCarbonell, F., Iturria‐Medina, Y., & Evans, A. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00037 · Cited by 74
“Their results provided an efficient ranking of multiple AD interventions, which might explain why recent single-target Aβ-based therapies failed to improve clinical outcomes in AD (118, 119).”
ResultKoch, G., Motta, C., Bonnì, S., Pellicciari, M. C., Picazio, S., Casula, E. P., Maiella, M., Lorenzo, F. D., Ponzo, V., Ferrari, C., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.10372 · Cited by 65
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 67
“A humanized version of the murine 3D6 antibody, bapineuzumab, entered into clinical trials for AD, where the AAA was administered by intravenous IV) infusion every 3 months at an infusion dose (ID) of 0.5, 1, or 2 mg/kg (Salloway et al, 2014).”
InfluentialFolic acid administration inhibits amyloid β-peptide accumulation in APP/PS1 transgenic mice
Li, W., Liu, H., Yu, M., Zhang, X., Zhang, M., Wilson, J. X., & Huang, G. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.03.009 · Cited by 62
“The transient nature of Aβ’s role in AD pathogenesis is underlined by recent phase 3 trials in which a humanized antiamyloid-beta monoclonal antibody failed to improve clinical outcomes in patients with AD [22].”
BackgroundImaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Ourselin, S., & Fox, N. C. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
“This finding was not replicated in the larger phase III study of noncarriers [22].”
BackgroundResultInfluentialSelf-citationMallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 69
“It should be noted, however, that the increased use of Aβ imaging in large-scale research studies and clinical trials has demonstrated a subset of both normal and cognitively impaired patients who have neurodegeneration biomarker changes without elevated Aβ, termed “suspected non–amyloid pathology” (SNAP), forwhich th…”
BackgroundResultInfluentialQu, L., Li, S., Ji, L., Luo, S., Ding, M., Yin, F., Wang, C., Luo, H., Lu, D., Liu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113889 · Cited by 61
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Van Kolen, K., Theunis, C., Mercken, M., & Kolb, H. C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 64
Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
Antonios, G., Borgers, H., Richard, B. C., Brauß, A., Meißner, J., Weggen, S., Pena, V., Pillot, T., Davies, S. L., Bakrania, P., et al. (2015) · Scientific Reports · doi:10.1038/srep17338 · Cited by 61
Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 67
Antibody Approaches To Treat Brain Diseases
Neves, V., Aires-da-Silva, F., Côrte-Real, S., & Castanho, M. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.10.005 · Cited by 56
Müller, W. E., Eckert, A., Eckert, G. P., Fink, H., Friedland, K., Gauthier, S. G., Hoerr, R., Ihl, R., Kasper, S. F., & Möller, H. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1308552 · Cited by 65
“…patients having early signs of neurodegeneration and cognitive decline or even the clinical diagnosis of mild AD without any evidence for Ab pathology (Wirth et al. 2013; Castello & Soriano 2014; Salloway et al. 2014; Caroli et al. 2015; Edmonds et al. 2015; Burnham et al. 2016; Jack et al. 2016).”
BackgroundCombined PET/MRI: Multi-modality Multi-parametric Imaging Is Here
Bailey, D. L., Pichler, B. J., Gückel, B., Barthel, H., Beer, A. J., Bremerich, J., Czernin, J. G., Drzezga, A. E., Franzius, C., Goh, V., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0886-9 · Cited by 74
“did not present the target for the drug [62].”
BackgroundCurrent and emerging brain applications of MR-guided focused ultrasound
Meng, Y., Suppiah, S., Mithani, K., Solomon, B., Schwartz, M. L., & Lipsman, N. (2017) · Journal of Therapeutic Ultrasound · doi:10.1186/s40349-017-0105-z · Cited by 66
“While they have proven to be effective both histologically and behaviorally in animal models and early clinical trials, there has yet to be an immunotherapy proven to be clinically effective in phase 3 clinical trials [81, 82].”
BackgroundAdvanced diffusion magnetic resonance imaging in patients with Alzheimer's and Parkinson's diseases
Kamagata, K., Andica, C., Hatano, T., Ogawa, T., Takeshige‐Amano, H., Ogaki, K., Akashi, T., Hagiwara, A., Fujita, S., & Aoki, S. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.276326 · Cited by 66
“However, the frequency of misdiagnosis of these diseases, which are diagnosed only based on clinical symptoms in clinical trials (Salloway et al., 2014), increases the need for objective biomarkers.”
BackgroundGlymphatic system dysfunction in neurodegenerative diseases
Beschörner, N., & Nedergaard, M. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001252 · Cited by 66
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 71
Wood, P. L., Locke, V. A., Herling, P., Passaro, A., Vigna, G. B., Volpato, S., Valacchi, G., Cervellati, C., & Zuliani, G. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2015.11.004 · Cited by 62
“Inclusion of multiple biochemical parameters to define the heterogeneity of patient groups will aid in avoiding errors such as occurred in clinical evaluations of anti-amyloid therapies in dementia patients with no amyloid deposition [5].”
Fiorito, J., Vendôme, J., Saeed, F., Staniszewski, A., Zhang, H., Yan, S., Deng, S., Arancio, O., & Landry, D. W. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00979 · Cited by 60
Martínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 68
Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease
Li, T.-R., Wang, X.-N., Sheng, C., Li, Y.-X., Li, F. Z.-T., Sun, Y., & Han, Y. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111175 · Cited by 60
Pan, X., Chen, Z., Fei, G., Pan, S., Bao, W., Ren, S., Guan, Y., & Zhong, C. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0067-0 · Cited by 59
Artificial intelligence in drug development: reshaping the therapeutic landscape
Niazi, S. K., & Mariam, Z. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251321704 · Cited by 82
Delnomdedieu, M., Duvvuri, S., Li, D. J., Atassi, N., Lu, M., Brashear, H. R., Liu, E., Ness, S., & Kupiec, J. W. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0177-y · Cited by 59
“Background To date, phase 3 immunotherapy trials with humanized monoclonal antibodies (mAb) targeting cerebral amyloid in patients with mild to moderate Alzheimer’s disease (AD) have not shown significant improvements in cognitive or functional outcomes [1, 2].”
BackgroundResultSelf-citationEmerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 59
“centric drugs for the treatment of AD such as the γ-secretase inhibitors avagacestat [97] and semagacestat [98] and the monoclonal antibody bapineuzumab [82] and the absence of marked beneficial effects for solanezumab [83] suggested that earlier intervention should be probably attempted with secondary prevention tria…”
BackgroundResultThomas, M. H., Pelleïeux, S., Vitale, N., & Olivier, J. L. (2016) · Biochimie · doi:10.1016/j.biochi.2016.07.013 · Cited by 62
SIRT1 as a therapeutic target for Alzheimer’s disease
Wong, S. Y., & Tang, B. L. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0023 · Cited by 61
Protein aggregation, misfolding and consequential human neurodegenerative diseases
Sami, N., Rahman, S., Kumar, V., Zaidi, S., Islam, A., Ali, S., Ahmad, F., & Hassan, M. I. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2017.1286339 · Cited by 64
Scuteri, D., Morrone, L. A., Rombolà, L., Avato, P., Bilia, A. R., Corasaniti, M. T., Sakurada, S., Sakurada, T., & Bagetta, G. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/9416305 · Cited by 73
Cai, X., Zhang, K., Xie, X., Zhu, X., Feng, J., Jin, Z., Zhang, H., Tian, M., & Chen, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119678 · Cited by 60
Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab
Sveikata, L., Charidimou, A., & Viswanathan, A. (2021) · Stroke · doi:10.1161/strokeaha.121.036873 · Cited by 63
Abate, G., Frisoni, G. B., Bourdon, J., Piccirella, S., Memo, M., & Uberti, D. L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00732-0 · Cited by 62
The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease
Verma, A., Waiker, D. K., Bhardwaj, B., Saraf, P., & Shrivastava, S. K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105562 · Cited by 60
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Heidebrink, J. L., & Paulson, H. L. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-051022-043645 · Cited by 70
“Over the past decade, numerous monoclonal antibodies have been studied in individuals with symptomatic AD (Table 1) (9–16).”
Developing therapeutic vaccines against Alzheimer’s disease
Wisniewski, T., & Drummond, E. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 59
“observed in either ApoE4 carriers or non-carriers at any dose.[62] Furthermore, ARIA-E was observed in 15% of ApoE4 carriers who received bapineuzumab”
BackgroundMethodMoonga, I., Niccolini, F., Wilson, H., Pagano, G., Politis, M., & Initiative, T. A. D. N. (2017) · European Journal of Neurology · doi:10.1111/ene.13374 · Cited by 61
The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia
Tasaki, S., Gaiteri, C., Mostafavi, S., De Jager, P. L., & Bennett, D. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00699 · Cited by 59
Kumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S., & Thorne, R. G. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00548 · Cited by 70
Espay, A. J., & Lang, A. E. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181465 · Cited by 61
Ghosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 58
Amyloid imaging for dementia in clinical practice
O’Brien, J. T., & Herholz, K. (2015) · BMC Medicine · doi:10.1186/s12916-015-0404-6 · Cited by 58
“The finding of a recent failed anti-amyloid study, namely that one-third of subjects entered were amyloid PET negative to begin with [20], supports the current view that an important application of amyloid PET is the appropriate stratification of subjects for therapeutic trials.”
Wang, G., Berry, S., Xiong, C., Hassenstab, J., Quintana, M., McDade, E. M., Delmar, P., Vestrucci, M., Sethuraman, G., Bateman, R. J., et al. (2018) · Statistics in Medicine · doi:10.1002/sim.7811 · Cited by 58
“Overall, these shortcomings have resulted in trial designs that require large sample sizes and long exposure to achieve acceptable statistical power.(2,6,7) We demonstrate that a disease progression model (DPM) built from the Dominantly Inherited Alzheimer Network (DIAN) observational cohort avoids each of these short…”
BackgroundVaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 56
“Phase III trials in mild-to-moderate Alzheimer’s disease reported no clinically relevant benefits over 78 weeks of treatment [10], whereas the occurrence of ARIA-E was an important adverse event related to bapineuzumab exposure, particularly at higher doses and among APOE-e4 carriers [11].”
BackgroundAging-Dependent Mitophagy Dysfunction in Alzheimer’s Disease
Song, M., Zhao, X., & Song, F. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02248-y · Cited by 60
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 65
Insights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 68
“90 Solanezumab and Crenezumab showed no evidence of a reduction in tau biomarkers in CSF and PET.”
Vallés, A. S., Borroni, M. V., & Barrantes, F. J. (2014) · CNS Drugs · doi:10.1007/s40263-014-0201-3 · Cited by 66
Posner, H. B., Curiel, R. E., Edgar, C. J., Hendrix, S. B., Liu, E., Loewenstein, D., Morrison, G., Shinobu, L. A., Wesnes, K. A., & Harvey, P. D. (2017) · PubMed Central · Cited by 68
Self-citationThe Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230099 · Cited by 53
Jack, C. R., Therneau, T. M., Lundt, E. S., Wiste, H. J., Mielke, M. M., Knopman, D. S., Graff-Radford, J., Lowe, V. J., Vemuri, P., Schwarz, C. G., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac017 · Cited by 56
Nasr, S. H., Kouyoumdjian, H., Mallett, C. L., Ramadan, S., Zhu, D. C., Shapiro, E. M., & Huang, X. (2017) · Small · doi:10.1002/smll.201701828 · Cited by 57
Kamei, N., Okada, N., Ikeda, T., Choi, H., Fujiwara, Y., Okumura, H., & Takeda‐Morishita, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-36210-9 · Cited by 60
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK
Cummings, J., Aisen, P., Barton, R., Bork, J., Doody, R., Dwyer, J., Egan, J. C., Feldman, H., Lappin, D., Truyen, L., et al. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.93 · Cited by 55
“Recent studies have shown that approximately 20% of patients diagnosed with AD dementia and included in trials have no amyloid burden in the brain as determined by amyloid positron emission tomography (PET) (14, 15).”
BackgroundSelf-citationVenkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 56
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C., Cho, H.-J., & Ryu, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 53
Systems biology of neurodegenerative diseases
Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015) · Integrative Biology · doi:10.1039/c5ib00031a · Cited by 53
Alzheimer's disease: Only prevention makes sense
Viña, J., & Sanz‐Ros, J. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13005 · Cited by 57
“As stated earlier, these favourable effects were not accompanied by any improvement in cognition.(4) An entirely different approach was used when researchers tried to modulate γ‐secretase activity.”
BackgroundFazlollahi, A., Calamante, F., Liang, X., Bourgeat, P., Raniga, P., Doré, V., Fripp, J., Ames, D. J., Masters, C. L., Rowe, C. C., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26810 · Cited by 59
Verger, A., Yakushev, I. Y., Albert, N. L., van Berckel, B. N. M., Brendel, M., Cecchin, D., Fernandez, P. A., Fraioli, F., Guedj, É., Morbelli, S. D., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06177-5 · Cited by 60
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
“Phase 3 Expedition 3 clinical trial with solanezumab at 400 mg monthly infusions showed an inability to significantly reduce amyloid cortical burden (with no related ARIA-E or ARIA-H) [71].”
BackgroundInfluentialDhage, P. A., Sharbidre, A. A., Dakua, S. P., & Balakrishnan, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111634 · Cited by 54
Zielinski, M., Reyes, F. S. P., Gremer, L., Schemmert, S., Frieg, B., Schäfer, L. U., Willuweit, A., Donner, L., Elvers, M., Nilsson, L. N. G., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01484-4 · Cited by 53
Blood protein predictors of brain amyloid for enrichment in clinical trials?
Ashton, N. J., Kiddle, S. J., Graf, J., Ward, M., Baird, A. L., Hye, A., Westwood, S., Wong, K. V., Dobson, R. J., Rabinovici, G. D., et al. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.005 · Cited by 54
“The availability of longer lived [18] F- labeled Ab PET tracers, such as flutemetamol [8] and florbetapir [9] could foster wider usage in the clinic [10].”
BackgroundShao, H., Zhang, Y., Dong, Y., Yu, B., Xia, W., & Xie, Z. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132792 · Cited by 53
“Recently, bapineuzumab, a humanized anti-amyloid-β (Aβ) monoclonal antibody [3], and solanezumab, another humanized monoclonal antibody [4] failed to improve cognitive function in AD patients.”
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease
Novak, G., Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. C., Gregg, K., Di, J., Collins, P., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150448 · Cited by 53
“This was not apparent for the clinical outcomes [10].”
InfluentialSelf-citationCeyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 51
Structural and Functional Hippocampal Changes in Subjective Cognitive Decline From the Community
Liang, L., Zhao, L., Wei, Y., Mai, W., Duan, G., Su, J., Nong, X., Yu, B., Li, C., Mo, X., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00064 · Cited by 64
Cho, H., Sharma, A. K., Zhang, Y., Gross, M. L., & Mirica, L. M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00114 · Cited by 59
Tian, M., Zuo, C., Civelek, A. C., Carrió, I., Watanabe, Y., Kang, K. W., Murakami, K., Garibotto, V., Prior, J. O., Barthel, H., et al. (2022) · Phenomics · doi:10.1007/s43657-022-00068-9 · Cited by 56
“1% of noncarriers) (Salloway et al. 2014), sug‐ gesting that the clinical diagnosis is unreliable to identify underlying pathology, especially when the care‐providing physicians are general practitioners rather than dementia specialists.”
BackgroundThe evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 68
Mably, A. J., Liu, W., Mc Donald, J. M., Dodart, J.-C., Bard, F., Lemere, C. A., O'Nuallain, B., & Walsh, D. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.008 · Cited by 53
Physiological IgM Class Catalytic Antibodies Selective for Transthyretin Amyloid
Planque, S. A., Nishiyama, Y., Hara, M., Sonoda, S., Murphy, S. K., Watanabe, K., Mitsuda, Y., Brown, E. L., Massey, R. J., Primmer, S. R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557231 · Cited by 54
Hua, X., Ching, C. R. K., Mezher, A. F., Gutman, B. A., Hibar, D. P., Bhatt, P. R., Leow, A., Jack, C. R., Bernstein, M. A., Weiner, M. W., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.018 · Cited by 59
Feinberg, H., Saldanha, J. W., Diep, L., Goel, A., Widom, A., Veldman, G. M., Weis, W. I., Schenk, D., & Basi, G. S. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt261 · Cited by 52
“Although the initial clinical trials with bapineuzumab failed to achieve the clinical end-points at the disease stage tested [11], the continued refinement of Aβ targeted immunotherapy for AD has resulted in numerous follow-on passive and active immunotherapy approaches currently undergoing clinical investigation.”
Buechler, J., & Salinas, P. C. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00038 · Cited by 51
“Multiple Aβ-targeting treatments have failed to produce appreciable cognitive benefits in AD clinical trials in recent years (Holmes et al., 2008; Doody et al., 2013, 2014; Vellas et al., 2013; Salloway et al., 2014).”
BackgroundDrzezga, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.206300 · Cited by 52
“For example, in a large study on AD treatment, many patients diagnosed with typical AD by expert clinical raters had no AD-typical neuropathologic findings on imaging (45).”
Modeling neurological disorders using brain organoids
Zhang, D. Y., Song, H., & Ming, G. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.026 · Cited by 54
Molecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 50
“For example, several notable trials of monoclonal antibodies directed at Ab-amyloid appeared to successfully reduce Ab-amyloid, but similar to trials inhibiting b- and g-secretases, they showed no significant improvement in cognition (33,34).”
ResultExploring the dual character of metformin in Alzheimer's disease
Ning, P., Luo, A., Mu, X. L., Xu, Y., & Li, T. X. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108966 · Cited by 53
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecìć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 56
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Alavi, A. A., Kepp, K. P., Sensi, S. L., Perry, G. L., Robakis, N. K. R. K., Barrio, J. R., & Vissel, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101996 · Cited by 56
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Panza, F., Solfrizzi, V., Imbimbo, B. P., Giannini, M., Santamato, A., Seripa, D., & Logroscino, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945522 · Cited by 53
“Bapineuzumab-treated patients had a reduced CSF phospho-tau concentrations and, among APOE-e4-carriers, a decreased rate of accumulation of cortical amyloid in the brain on (11)C PiB PET [29].”
BackgroundResultInfluentialBlood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly
Westwood, S., Leoni, E., Hye, A., Lynham, S., Khondoker, M. R., Ashton, N. J., Kiddle, S. J., Baird, A. L., Sáinz‐Fuertes, R., Leung, R., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151155 · Cited by 53
“Although there have been considerable advances in our understanding of Alzheimer’s disease (AD), the results of clinical trials testing AD treatments have so far been disappointing [1, 2].”
BackgroundSacuiu, S. F. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00008-2 · Cited by 73
The emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 50
“The majority of clinical trials in AD have focused on amyloid therapies (for example, see references 96–98), also including serial amyloid-PET scans to evaluate decreases in cerebral amyloid burden 97,98 .”
BackgroundHow technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study.
Au, R., Piers, R. J., & Devine, S. (2017) · Neuropsychology · doi:10.1037/neu0000411 · Cited by 49
“Further, the continued failure of clinical trial studies reflects, in part, treatment interventions that are too late to reverse course of the disease (Sperling, Karlawish, & Johnson, 2013; Salloway et al., 2014; Doody et al., 2014; Belluck, 2016; Taylor, 2017).”
BackgroundAntibody Therapeutics Targeting Aβ and Tau
Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 50
“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50
Aranda, M., Márquez, D. X., Gallagher-Thompson, D. E., Pérez, A., Rojas, J. C., Hill, C. V., Reyes, Y., Dilworth‐Anderson, P., & Portacolone, E. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12389 · Cited by 63
Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged
Rothstein, T. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00127 · Cited by 56
Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer’s Disease
Kwak, K.-A., Lee, S., Yang, J.-Y., & Park, Y. (2018) · Stem Cells International · doi:10.1155/2018/6392986 · Cited by 54
Metadata
- Authors
- Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Sahlgrenska University Hospital (SE)
- University of Pittsburgh (US)
- Veterans Health Administration (US)
- Columbia University (US)
- University of Rochester Medicine (US)
- NYU Langone Health (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 322-333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4159618
- OpenAlex
- W2063808031
- Semantic Scholar
- e062a2c7d07a68f95ef3d0dad78aaa50b786274d
- Cited by
- 1,960
- References
- 35
- Citations by year
- 2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
- FWCI
- 158.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001820)
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
- National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.